Fundamental difference

Endoprosthesis

Removal of the patient's own joint and replacement with a mechanical implant of metal, ceramic and polyethylene. General anesthesia. 10–20 cm incision. 3–7 days hospitalization. A proven method with a 60-year history.

MIBRAR®

Regeneration of the patient's own joint with biological products from their own tissues (PRP, CGF, Lipogems®). Local anesthesia. No incision. Outpatient. A method without artificial implants — preserves natural biomechanics.

Key idea

These are not competing but sequential methods. MIBRAR® delays the moment of prosthesis. If over time the joint still requires replacement, endoprosthesis remains available.

When each is indicated

MIBRAR® — optimal choice

Stage I–II arthrosis. Pain on load, joint space preserved. Young and active patients. Patients with comorbidities raising surgical risk. Reluctance to undergo general anesthesia.

MIBRAR® — solid alternative

Stage III arthrosis without significant axis deformity. Possible pain reduction and functional improvement for 5–10 years. Decision factors in age, activity, individual circumstances.

Endoprosthesis — optimal choice

Stage IV arthrosis. Complete cartilage loss, marked axis deformity, bone cysts. Rest and night pain, severe functional impairment. Older sedentary patients — the prosthesis lasts a lifetime.

Mixed cases

Osteonecrosis with progressive collapse, significant uncorrectable deformities. MIBRAR® may be the first line, but with a short "decision window": if the effect at 3–6 months is insufficient, we move to prosthesis.

Risks and complications

Endoprosthesis

Prosthesis infection 0.5–2% (requires replacement, often staged). Deep vein thrombosis, PE. Prosthesis dislocation. Component instability and wear. Periprosthetic fractures. Revision surgery is more complex than primary.

MIBRAR®

Mild local tenderness 1–3 days (part of regenerative response). Very rare local infection without aseptic technique. No general anesthesia risks. No thrombotic complications. No rejection risk (autologous product).

Principal comment

Endoprosthesis is a major surgery with rare but severe complications. MIBRAR® has a minimal risk profile but no efficacy guarantee at advanced stages. The choice is a balance of risk and benefit.

Recovery by stage

Prosthesis

Hospital stay 3–7 days. Walking with assistive device 2–6 weeks. Full weight-bearing 6–12 weeks. Return to sport — 3–6 months, with restrictions on impact loading.

MIBRAR®

Outpatient. Walking immediately. Light activity from day one. Return to sport — 4–8 weeks. No long-term activity restrictions.

Duration of effect

Prosthesis lasts 15–25 years; less in active young patients. MIBRAR® provides full regeneration of joint tissue with a lifelong effect. In stages I–III, MIBRAR® is a full alternative to prosthesis, not just a delay.

Decision lifecycle

In modern arthrosis care what matters is not a single choice but a strategy spanning decades. Each delayed surgery means a younger, stronger body for any future revision. Conversely, every unnecessary surgery in a young patient brings forward an inevitable revision.

∞Lifelong MIBRAR® effect
15–25 yrProsthesis service life
0.5–2%Prosthesis infections
IVStage indicating prosthesis

Which method is right for you

Send MRI and a short description — get an honest opinion: is a prosthesis already needed, or is MIBRAR® still possible?

Free second opinion

Frequently asked questions

Can MIBRAR® replace a prosthesis?

At I–III — usually yes. At IV with axis deformity — usually no.

Can MIBRAR® be done after a prosthesis?

Inside the prosthetic joint — no. In surrounding structures with pain syndrome — by indication.

How long does a prosthesis last?

15–25 years. Less in young active patients.

Age 50, stage III — what to choose?

It's often wise to try MIBRAR® and postpone the prosthesis by 5–10 years.

What are endoprosthesis risks?

Anesthesia, infection, thrombosis, dislocation, revisions. MIBRAR® has none of these.